Laboratorios ROVI publishes 1Q 2026 results
Operating income reaches 152.5 million euros. CDMO grows 5%, Risperidona ISM® 37%. R&D investment rises 79% to 11.2 million.
See the latest news and media coverage for Rovi. We track all announcements, press releases, and industry mentions in real time, all in one place.
Specialty pharmaceutical company
rovi.esLast updated
In short: Rovi expanded its global manufacturing footprint into the US and signed key agreements with Roche while managing a transitional financial period.
Operating income reaches 152.5 million euros. CDMO grows 5%, Risperidona ISM® 37%. R&D investment rises 79% to 11.2 million.
Gross margin expands 3.8 points to 62.3%. Heparin sales drop 12%, Okedi rises 37%. Updates 2026 guidance to low-to-mid single-digit growth. Announces plant acquisition completion.
Beatriz de Zavala Mazarredo will present them in streaming with Estrategias de inversión at 12:30 p.m.
Beatriz de Zavala Mazarredo will present them on May 6 at 11:00 in live broadcast.
The company confirms its commitment to growth despite the profit warning announced in May. It believes that the Domínguez family's decision to raise its...
Indumenta Pueri, investment holding of the Domínguez de la Maza family and owners of Mayoral, has increased its stake in Rovi to 13.439%, consolidating...
Indumenta Pueri, the investment holding company of the Domínguez de la Maza family, owners of the children's clothing brand Mayoral, has increased its stake in...
The Government has reduced by 25% the contribution that several pharmaceutical companies such as Grifols, Almirall and Rovi make to the National Health System.
Track Rovi and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Rovi and other trending companies.